BMY/Opdivo, MRK/Keytruda: While both companies appear to be doing well with their respective products, both need much better[now ~ 20-25%] patient RRRs in the respective solid tumors each is targeting to reach their full potential, IMO. Has anyone heard/read any published data where substantially increased RRRs have been achieved with the respective combination IO therapies each of MRK or BMY is engaged in exploring? There are a lot of tumor target moieties that apparently suppress the immune system, allowing the tumor to escape therapy.
Market Data 
Markets 
AI
